

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Haft Nicholas</u>			2. Issuer Name and Ticker or Trading Symbol <u>Finch Therapeutics Group, Inc. [FNCH]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/23/2021					
C/O FINCH THERAPEUTICS GROUP, INC. 200 INNER BELT ROAD, SUITE 400			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Street)	(City)	(State) (Zip)	SOMERVILLE MA 02143					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/23/2021		C		172,942	A	(1)	172,942	I	See footnote ⁽²⁾
Common Stock	03/23/2021		C		143,831	A	(1)	143,831	I	See footnote ⁽³⁾
Common Stock	03/23/2021		C		1,064,466	A	(1)	1,064,466	I	See footnote ⁽⁴⁾
Common Stock	03/23/2021		C		366,093	A	(1)	1,430,559	I	See footnote ⁽⁴⁾
Common Stock	03/23/2021		C		212,893	A	(1)	212,893	I	See footnote ⁽⁵⁾
Common Stock	03/23/2021		C		1,150,481	A	(1)	1,150,481	I	See footnote ⁽⁶⁾
Common Stock	03/23/2021		P		882,351	A	\$17	882,351	I	See footnote ⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series A Preferred Stock	(1)	03/23/2021		C			172,942	(1)	(1)	Common Stock	172,942	\$0.00	0	I	See footnote ⁽²⁾
Series A Preferred Stock	(1)	03/23/2021		C			143,831	(1)	(1)	Common Stock	143,831	\$0.00	0	I	See footnote ⁽³⁾
Series B Preferred Stock	(1)	03/23/2021		C			1,064,466	(1)	(1)	Common Stock	1,064,466	\$0.00	0	I	See footnote ⁽⁴⁾
Series C Preferred Stock	(1)	03/23/2021		C			366,093	(1)	(1)	Common Stock	366,093	\$0.00	0	I	See footnote ⁽⁴⁾
Series C Preferred Stock	(1)	03/23/2021		C			212,893	(1)	(1)	Common Stock	212,893	\$0.00	0	I	See footnote ⁽⁵⁾
Series D Preferred Stock	(1)	03/23/2021		C			1,150,481	(1)	(1)	Common Stock	1,150,481	\$0.00	0	I	See footnote ⁽⁶⁾

Explanation of Responses:

- Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.
- The securities are held by M3 Ventures - Finch LLC ("M3 Ventures I"). The Reporting Person is the manager of M3 Ventures I.
- The securities are held by NBTT 2 Investments LLC ("NBTT"). The Reporting Person is the manager of NBTT.
- The securities are held by M3 Ventures - Finch II LLC ("M3 Ventures II"). The Reporting Person is the manager of M3 Ventures II.
- The securities are held by Arcos Ventures SPV LLC ("Arcos"). The Reporting Person is the manager of Arcos.
- The securities are held by OMX Ventures SPV-Finch LLC ("OMX I"). The Reporting Person is the manager of OMX I.
- The securities are held by OMX Ventures SPV-Finch II LLC ("OMX II"). The Reporting Person is the manager of OMX II.

Remarks:

/s/ Jason Minio, Attorney-in-Fact

03/25/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.